Surrey researchers Sign in
Back
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
Journal article   Peer reviewed

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer

JS de Bono, JM Piulats, HS Pandha, DP Petrylak, F Saad, LMA Aparicio, SK Sandhu, P Fong, S Gillessen, GR Hudes, …
CLINICAL CANCER RESEARCH, Vol.20(7), pp.1925-1934
01/04/2014
DOI: https://doi.org/10.1158/1078-0432.CCR-13-1869

Abstract

Science & Technology Life Sciences & Biomedicine Oncology ONCOLOGY GROWTH-FACTOR RECEPTOR IN-VIVO INCREASED SURVIVAL CLINICAL-TRIALS SOLID TUMORS DOUBLE-BLIND OPEN-LABEL IGF-IR INSULIN PREDNISONE
url
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000333900000026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11d2a86992e85fb529977dad66a846d5View
Author

Metrics

34 Record Views
40 Times Cited - Web of Science

Details

Usage Policy

Usage details for all content viewed and downloaded in this site are shared with IRUS-UK (Institutional Repository Usage Statistics UK). Cookies are used to remember your decision. Click Accept to accept usage details sharing and the cookies.

Learn more